SEC Comment Letter for OptimizeRx Corp (OPRX) (CIK 0001448431) (OPRX) — Jun 14, 2016
OptimizeRx Corp (OPRX) (CIK 0001448431)
Date: June 14, 2016 · CIK: 0001448431 · Accession: 0000000000-16-080446
AI Filing Summary & Sentiment
File numbers found in text: 333-211862
Letter
Mail Stop 4561 June 14, 2016 William J. Febbo Chief Executive Officer OptimizeRx Corp. 400 Water Street, Suite 200 Rochester, MI 48307
Re: OptimizeRx Corp. Registration Statement on Form S-1 Filed June 6, 2016 File No. 333-211862
Dear Mr. Febbo :
This is to advise you that we have not reviewed and will not review your registration statement .
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that:
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action wit h respect to the filing;
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in th e filing; and
the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
William J. Febbo OptimizeRx Corp. June 14, 2016 Page 2
Please refer to Rule 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities unde r the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities .
Please contact Ji Shin, Attorney -Advisor, at (202) 551 -3579, or me at (202) 551 -3453 with any other questio ns.
Sincerely,
/s/ Jan Woo
Show Raw Text
Mail Stop 4561 June 14, 2016 William J. Febbo Chief Executive Officer OptimizeRx Corp. 400 Water Street, Suite 200 Rochester, MI 48307 Re: OptimizeRx Corp. Registration Statement on Form S-1 Filed June 6, 2016 File No. 333-211862 Dear Mr. Febbo : This is to advise you that we have not reviewed and will not review your registration statement . We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that: should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action wit h respect to the filing; the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in th e filing; and the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. William J. Febbo OptimizeRx Corp. June 14, 2016 Page 2 Please refer to Rule 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities unde r the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities . Please contact Ji Shin, Attorney -Advisor, at (202) 551 -3579, or me at (202) 551 -3453 with any other questio ns. Sincerely, /s/ Jan Woo Jan Woo Branch Chief – Legal Office of Information Technologies and Services cc: Scott Doney, Esq. The Doney Law Firm